Skip to content
drillr.ai

DYAI

Dyadic International, Inc.

NASDAQ · USHealthcareBiotechnology
$1.21-3.97%

Price as of Jul 20, 2026

DYAI news

Dyadic International, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

    JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its pro

    Globe Newswire ·

  2. Dyadic Expands IP Protection and Business Development Activities in Japan

    JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinan

    Globe Newswire ·

  3. An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

    SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) ("Dyadic" or the "Company") is entering the next phase of its growth strategy as it expands commercialization efforts across Life Sciences, Food & Nutrition, and Bio-industrial markets. SmallCaps Daily sat down with President and Chief Operating Officer Joe Haz

    Newsfile Corp ·

  4. Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

    JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms, today highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as

    Globe Newswire ·

  5. Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

    JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical applications, today announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to e

    Globe Newswire ·

  6. Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

    New York, NY, May 21, 2026 (GLOBE NEWSWIRE) -- Skyline Corporate Communications Group, LLC (“Skyline”), an investor relations and corporate communications firm headquartered in New York, today announced that Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”, “the Company”), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will present at the Skyline Signature Series™ on Wednes

    Globe Newswire ·

  7. Sidoti Events, LLC's May Micro-Cap Virtual Conference

    NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference taking place Wednesday and Thursday, May 20-21, 2026. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links. (https://app.accessnewswire.com/imagelibrary/1af07b01-4e5d-4dad-

    ACCESSWIRE ·

  8. Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

    JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced that Joe Hazelton, Dyadic’s President and Chief Operating Officer, will present at Sidoti’s Virtual Investor Conference on May 20-21, 2026. Dyadic’s presentation is scheduled t

    Globe Newswire ·

  9. Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

    * Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales * Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership * Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant DNase

    Globe Newswire ·

  10. Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

    JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications today announced that it has entered into an original equipment manufacturer (“OEM”) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices (“IBT”), a life sciences r

    Globe Newswire ·

  11. Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11(th) – 12(th), are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging

    Globe Newswire ·

  12. Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE (https://www.globenewswire.com/Tracker?data=9hB4Q2KQrOo6hXj8yEqbP9TkusAHR695Pohm7zgv7dE22DllUsKZ3uFpHiGwBgvgw8BUEKeCzouQXkLjuR1wti3kH25dFirtThHEfRwPeFZDygiDJtWeK

    Globe Newswire ·

  13. Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

    JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Inzymes ApS (“Inzymes”), a Denmark-based enzyme company specializing in the development, scale-up, and commercialization of enzymes for sustainable food and beverage appli

    Globe Newswire ·